{"entity":{"id":"kara-kelly","kind":"person","name":"Kara M. Kelly","aka":[],"tldr":"Leads the COG Hodgkin lymphoma committee and the trials bringing brentuximab and nivolumab to children with the disease.","summary":"Kara Kelly chairs the Children's Oncology Group Hodgkin lymphoma committee and was study chair of AHOD1331, which showed brentuximab vedotin with chemotherapy improves event-free survival in high-risk paediatric Hodgkin lymphoma and led to the first paediatric approval, and co-leads AHOD2131 testing nivolumab with reduced therapy. Her work focuses on curing children with fewer late effects.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20KM%5BAuthor%5D%20Hodgkin%20children"}],"tags":["paediatric","hodgkin","cooperative-group"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["brentuximab-vedotin","nivolumab"],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":["ahod2131","swog-s1826"],"people":[],"bottlenecks":[],"keyPapers":["paper-swog-s1826-nivolumab-avd-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Pediatric Oncology, Roswell Park Comprehensive Cancer Center; Division Chief, Pediatric Hematology/Oncology, University at Buffalo","institutionId":"roswell-park","specialisms":["Paediatric Hodgkin lymphoma","Response-adapted therapy","Cooperative-group trials","Survivorship"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20KM%5BAuthor%5D%20Hodgkin%20children"}],"papers":[{"title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma (AHOD1331)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2206660"},{"title":"Nivolumab plus AVD in advanced-stage classic Hodgkin's lymphoma (SWOG S1826)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2405888"}]},"route":"/people/kara-kelly/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","route":"/institutions/roswell-park/"}],"trial":[{"id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","route":"/trials/ahod2131/"},{"id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/"}],"paper":[{"id":"paper-swog-s1826-nivolumab-avd-nejm-2024","kind":"paper","name":"SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults","route":"/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/"}]}}